ArticleChild and adolescent psychiatry and mental health2009
Change in the direct cost of treatment for children and adolescents with hyperkinetic disorder in Germany over a period of four years.
Article in Child and adolescent psychiatry and mental health, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 21 citations in OpenAlex.
- Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.PharmacoEconomics · 2012Trial
- Health care and societal costs of the management of children and adolescents with attention-deficit/hyperactivity disorder in Spain: a descriptive analysis.BMC psychiatry · 2018Article
- Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.The European journal of health economics : HEPAC : health economics in prevention and care · 2017Article
- Costs and treatment patterns of incident ADHD patients - a comparative analysis before and after the initial diagnosis.Health economics review · 2015Article
- Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case.European child & adolescent psychiatry · 2014Article
- Treatment costs of attention deficit hyperactivity disorder in Germany.The European journal of health economics : HEPAC : health economics in prevention and care · 2013Article
- [The health economics of attention deficit hyperactivity disorder in Germany. Part 1: Health care utilization and cost of illness].Der Nervenarzt · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn many developed countries, the treatment of hyperkinetic disorder (or ADHD) consumes a considerable amount of resources. The primary aim of this study was to determine change in the direct cost of treatment for children and adolescents with hyperkinetic disorder in Germany over time, and compare the cost with the cost of treatment for two physical disorders: epilepsy and asthma.
methodsThe German Federal Statistical Office provided data on the direct cost of treating hyperkinetic disorder, epilepsy and asthma in Germany for 2002, 2004, and 2006. The direct costs of treatment incurred by hyperkinetic disorder in these years were compared with those incurred by epilepsy and asthma.
resultsThe total direct cost of treatment for the hyperkinetic disorder was euro 177 million in 2002, euro 234 million in 2004, and euro 341 million in 2006. The largest proportion of the cost was incurred by the age group < 15 years: euro 158 million in 2002, euro 205 million in 2004, and euro 287 million in 2006. The direct cost of treatment for epilepsy in this age group was a total of euro 157 million in 2002, euro 155 million in 2004, and euro 155 million in 2006. For asthma, the total direct cost of treatment in this age group was euro 266 million in 2002, euro 257 million in 2004, and euro 272 million in 2006.
conclusionThe direct cost of treatment for hyperkinetic disorder in the age group < 15 years increased considerably between 2002 and 2006. Over the same period of time and for the same age group, expenditure for epilepsy and asthma was more or less constant. The increase in expenditure for the treatment of hyperkinetic disorder may be due to increasing demand for diagnostic and therapeutic services and improved availability of such services. The study is limited by the difficulty of obtaining consistent data on the direct cost of treatment for both physical and psychiatric disorders in Germany.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.